DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on September 20, 2005; DOI: 10.1124/dmd.105.005264

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.005264v1
33/12/1845    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murakami, Y.
Right arrow Articles by Yamamoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murakami, Y.
Right arrow Articles by Yamamoto, T.


Received for publication April 27, 2005.
Revised September 13, 2005.
Accepted for publication September 16, 2005.

Functional characterization of human monocarboxylate transporter 6 (SLC16A5)

Yuichi Murakami 1, Noriko Kohyama 2, Yasuna Kobayashi 2, Masayuki Ohbayashi 2, Hisakazu Ohtani 1, Yasufumi Sawada 3, Toshinori Yamamoto 2*

1 Graduate School of Pharmaceutical Sciences, Kyushu University 2 School of Pharmaceutical Sciences, Showa University 3 Graduate School of Pharmaceutical Sciences, The University of Tokyo

* Address correspondence to: E-mail: yamagen{at}pharm.showa-u.ac.jp

Abstract

Human monocarboxylate transporter 6 (MCT6) has recently been isolated and its tissue distribution has been established at the mRNA level, but its functional properties remain unknown. The aim of this study is to investigate the transport properties of MCT6. When expressed in Xenopus laevis oocytes, MCT6 transported [3H]bumetanide in a pH- and membrane potential-sensitive, but not proton gradient dependent manner, with the Kt value of 84 µM. Furthermore, MCT6 transported various drugs such as probenecid and nateglinide. Neither [14C]L-lactic acid nor [3H]L-tryptophan, typical substrates of other MCT isoforms, was transported by MCT6. Four loop diuretics, i.e. furosemide, piretanide, azosemide and torasemide, thiazides, probenecid, glibenclamide and nateglinide inhibited the MCT6-mediated uptake of [3H]bumetanide. In contrast, short-chain carboxylic acids, such as L-lactic acid and succinic acid did not inhibit the MCT6 mediated uptake of bumetanide. These results suggest that the substrate specificity of MCT6 is distinct from those of other MCTs. Bumetanide would be a good tool for investigating the functional properties of MCT6. It is probable that MCT6 is involved in the disposition of various drugs, including bumetanide.


Key words: drug transport, organic anion transport, transporters


This article has been cited by other articles:


Home page
 EndocrinologyHome page
H. Heuer and T. J. Visser
Pathophysiological Importance of Thyroid Hormone Transporters
Endocrinology, March 1, 2009; 150(3): 1078 - 1083.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.